Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy

Summary

The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are: I. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?

Eligibility

Inclusion Criteria:

* Presence of atrial fibrillation or atrial flutter not self-limited.
* Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) \<50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF \<50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%.
* Signature of informed consent.
* Ability to understand and accept participation in the study.

Exclusion Criteria:

* Refusal of informed consent.
* Legal or juridical incapacity.
* Age \<18 years.
* Life expectancy less than 1 year.
* Impossibility of a follow-up of at least 6 months.
* Presence of a ventricular rate \>140 beats per minute, limiting the validity of imaging measurements.
* Presence of known factors causing systolic ventricular dysfunction:

  * Prior cardiomyopathy diagnosis.
  * Severe mitral or aortic valve disease.
  * Non-revascularizable ischemic heart disease.
  * Context of peri-resuscitation cardiopulmonary care.
  * Abusive alcohol consumption, defined as \>80 grams of ethanol or \>7 standard alcoholic beverages per day.
  * Active treatment with chemotherapeutic agents or radiation therapy to the thorax.
  * Known infection with Trypanosoma cruzi, Borrellia burgdorferi or other infectious agent causing cardiomyopathy.

Conditions4

Browse More Trials